Who Generates Higher Gross Profit? Ascendis Pharma A/S or Bausch Health Companies Inc.

Pharma Giants' Gross Profit Battle: Ascendis vs. Bausch

__timestampAscendis Pharma A/SBausch Health Companies Inc.
Wednesday, January 1, 2014139830006008900000
Thursday, January 1, 201581180007853800000
Friday, January 1, 201646060007063000000
Sunday, January 1, 201715300006176000000
Monday, January 1, 2018105810006029000000
Tuesday, January 1, 2019133750006251000000
Wednesday, January 1, 202069530005778000000
Friday, January 1, 202142550006040000000
Saturday, January 1, 2022390370005760000000
Sunday, January 1, 20232223230006198000000
Monday, January 1, 2024319383000
Loading chart...

In pursuit of knowledge

A Tale of Two Companies: Gross Profit Showdown

In the competitive world of pharmaceuticals, Ascendis Pharma A/S and Bausch Health Companies Inc. have been vying for dominance in gross profit generation since 2014. While Ascendis Pharma A/S has shown impressive growth, with a staggering 1,500% increase in gross profit from 2014 to 2023, Bausch Health Companies Inc. consistently outpaces its rival, maintaining a gross profit that is approximately 20 times higher on average.

The Decade in Review

From 2014 to 2023, Bausch Health Companies Inc. has demonstrated remarkable stability, with gross profits peaking in 2015. In contrast, Ascendis Pharma A/S experienced a significant surge in 2023, marking its highest gross profit in the decade. This data highlights the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions can lead to dramatic shifts in financial performance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025